(CGEM) Cullinan Oncology - Ratings and Ratios
Zipalertinib, CLN-978, CLN-619, CLN-049, CLN-617
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 76.6% |
| Value at Risk 5%th | 113% |
| Relative Tail Risk | -10.38% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.20 |
| Alpha | -30.10 |
| CAGR/Max DD | 0.03 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.487 |
| Beta | 0.891 |
| Beta Downside | 0.289 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.41% |
| Mean DD | 40.31% |
| Median DD | 38.59% |
Description: CGEM Cullinan Oncology December 27, 2025
Cullinan Therapeutics (NASDAQ: CGEM) is a clinical-stage biotech focused on small-molecule and biologic therapies for oncology and autoimmune disorders. Its lead assets include zipalertinib, a bioavailable inhibitor now in a Phase 3 trial for non-small cell lung cancer (NSCLC), and CLN-978, a T-cell engager targeting systemic lupus erythematosus and rheumatoid arthritis. Additional early-stage programs comprise CLN-619 (monoclonal antibody for solid tumors and multiple myeloma), CLN-049 (bispecific antibody for AML/MDS and MRD-positive AML), and CLN-617 (fusion protein for solid tumors). The company collaborates with Adimab on antibody discovery and with Taiho Pharmaceutical on zipalertinib co-development; it rebranded from Cullinan Oncology to Cullinan Therapeutics in April 2024.
Key sector context: the global NSCLC market is projected to exceed $30 billion by 2028, while biotech R&D spending averages a 12 % YoY increase, pressuring cash-burn rates for companies in Phase 3. Historically, Phase 3 oncology trials have a ~30 % success probability, implying a material valuation upside if zipalertinib meets its primary endpoint. As of the latest filing, CGEM reported $85 million in cash and equivalents, sufficient for roughly 12 months of runway at its current burn rate.
For a deeper, data-driven look at CGEM’s valuation and risk profile, check out the analyst page on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.36 (>2.0%) and ΔFCFTA -16.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.36 (>3.0%) and CFO -174.3m > Net Income -216.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (59.0m) change vs 12m ago 1.16% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -11.97 (EBITDA TTM -236.1m / Interest Expense TTM -19.8m) >= 6 (WARN >= 3) |
Altman Z'' -19.41
| (A) 0.64 = (Total Current Assets 342.2m - Total Current Liabilities 32.8m) / Total Assets 484.1m |
| (B) -1.11 = Retained Earnings (Balance) -537.4m / Total Assets 484.1m |
| warn (B) unusual magnitude: -1.11 — check mapping/units |
| (C) -0.42 = EBIT TTM -236.5m / Avg Total Assets 568.7m |
| (D) -16.38 = Book Value of Equity -536.4m / Total Liabilities 32.8m |
| Total Rating: -19.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.35
| 1. Piotroski 0.0pt |
| 2. FCF Yield -65.42% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda 0.43 |
| 6. ROIC - WACC (= -54.66)% |
| 7. RoE -41.58% |
| 8. Rev. Trend 42.01% |
| 9. EPS Trend -33.25% |
What is the price of CGEM shares?
Over the past week, the price has changed by +5.70%, over one month by -12.06%, over three months by +85.74% and over the past year by -5.36%.
Is CGEM a buy, sell or hold?
- Strong Buy: 8
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CGEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.1 | 165.8% |
| Analysts Target Price | 29.1 | 165.8% |
| ValueRay Target Price | 12.2 | 11.5% |
CGEM Fundamental Data Overview January 04, 2026
P/E Forward = 6.3012
P/S = 26.8794
P/B = 1.3546
Beta = -0.098
Revenue TTM = 0.0 USD
EBIT TTM = -236.5m USD
EBITDA TTM = -236.1m USD
Long Term Debt = 1.19m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.19m USD (from shortTermDebt, last quarter)
Debt = 1.19m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.1m USD (from netDebt column, last quarter)
Enterprise Value = 266.4m USD (597.9m + Debt 1.19m - CCE 332.6m)
Interest Coverage Ratio = -11.97 (Ebit TTM -236.5m / Interest Expense TTM -19.8m)
FCF Yield = -65.42% (FCF TTM -174.3m / Enterprise Value 266.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 230.0k) / Revenue TTM)
Tobins Q-Ratio = 0.55 (Enterprise Value 266.4m / Total Assets 484.1m)
Interest Expense / Debt = 388.5% (Interest Expense 4.62m / Debt 1.19m)
Taxrate = -0.07% (negative due to tax credits) (117.0k / -167.5m)
NOPAT = -236.6m (EBIT -236.5m * (1 - -0.07%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 10.45 (Total Current Assets 342.2m / Total Current Liabilities 32.8m)
Debt / Equity = 0.00 (Debt 1.19m / totalStockholderEquity, last quarter 451.4m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -102.1m / EBITDA -236.1m)
Debt / FCF = 0.59 (negative FCF - burning cash) (Net Debt -102.1m / FCF TTM -174.3m)
Total Stockholder Equity = 521.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.78% (Net Income -216.8m / Total Assets 484.1m)
RoE = -41.58% (Net Income TTM -216.8m / Total Stockholder Equity 521.4m)
RoCE = -45.24% (EBIT -236.5m / Capital Employed (Equity 521.4m + L.T.Debt 1.19m))
RoIC = -45.38% (negative operating profit) (NOPAT -236.6m / Invested Capital 521.4m)
WACC = 9.28% (E(597.9m)/V(599.0m) * Re(9.30%) + (debt cost/tax rate unavailable))
Discount Rate = 9.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 7.19%
Fair Price DCF = unknown (Cash Flow -174.3m)
EPS Correlation: -33.25 | EPS CAGR: 5.46% | SUE: 3.78 | # QB: 1
Revenue Correlation: 42.01 | Revenue CAGR: 89.54% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.91 | Chg30d=-0.017 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=-3.32 | Chg30d=+0.039 | Revisions Net=+1 | Growth EPS=+8.0% | Growth Revenue=+231.7%
Additional Sources for CGEM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle